-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3618 Poor Survival Outcomes Among Patients with Burkitt Lymphoma Are Associated with Socioeconomic Disparities

Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Lymphoid Malignancies: Poster II
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Lymphomas, non-Hodgkin lymphoma, epidemiology, B Cell lymphoma, Clinical Research, health outcomes research, health disparities research, Diseases, aggressive lymphoma, Lymphoid Malignancies, survivorship
Sunday, December 11, 2022, 6:00 PM-8:00 PM

Oluwasegun Akinyemi, MD1,2*, Faith O Abodunrin, MD3, Oluwatayo Adeoye, MD4*, Akinwale Akingbule, MD, MS5*, Olanrewaju Oni, MD, MS6*, Bolarinwa Akinwumi, MD, MS7*, Ademola Ojo, MD8*, Oluwaseun B Ogunbona, MBBS PhD9* and Peter Silberstein, MD10*

1The Clive O. Callender Outcomes Research Center, Howard University College of Medicine, Macomb, IL
2Department of Health Policy and Management, University of Maryland School of Public Health, College Park, MD
3Department of Internal Medicine, Creighton University, OMAHA, NE
4Department of Internal Medicine, St Elizabeth's Medical Center, Boston, MA
5Department of Public Health, Ozark valley medical Clinic,, Branson, MO
6Department of Pathology, Howard University College of Medicine, Washington, DC
7Western Illinois University, Macomb, IL
8Department of Internal Medicine, Howard University College of Medicine, Washington, DC
9Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX
10Department of Medicine, Creighton University Medical Center, Omaha, NE

Introduction: Burkitt lymphoma is an aggressive non-Hodgkin B-cell lymphoma potentially fatal if left untreated. While the prognosis depends mainly on the histologic features and stage of the disease, it is usually poor in adult patients. The extent to which social determinants of health such as annual median income influence survival outcomes among patients with Burkitt lymphoma needs further exploration. In this study, we described the effect of race/ethnicity and socioeconomic factors on survival outcomes among patients with Burkitt lymphoma in the United States.

Methods: Using the Surveillance, Epidemiology, and End Results (SEER) 18 Registry, we extracted data on patients with a primary diagnosis of Burkitt lymphoma from 2007 to 2019. The primary outcome of interest was the overall survival of these patients. We utilized the cox regression model to determine the association between patients’ race/ethnicity, age, sex, annual median income, disease stage at presentation and treatment modalities, and overall patient survival. Utilizing the structural equation model, we determined the relative contribution of race/ethnicity, income, and sex to the disparities in survival.

Results: There were 3,578 patients with Burkitt lymphoma with complete survival data in the present study. 60.8% were Non-Hispanic Whites (NHW), 9.6% were Non-Hispanic Blacks (NHB), 19.5% were Hispanics, 8.9% were Non-Hispanic Asian or Pacific Islanders (NHAPI), and 1.4% were of other race/ethnicities. The one- and five-year survival by race/ethnicity was NHW (96.8%, 88.1%), NHB (94.8%,81.8%), Hispanics (97.9%,87.4%), NHAPI (96.7%, 85. 4%). Predictors of worse survival include increasing age, OR= 1.03 (95% CI 1.03-1.04, p <0.001) and racial status as NHB OR=1.85 (95% CI; 1.46-2.34, p= <0.001). Receiving chemotherapy, radiation therapy, and being in the highest income quintiles (defined as an annual income above $60,000) was associated with better survival. In the modeling analysis, the reduced survival among NHBs is partially attributable to lower income and reduced access to treatment modalities. There was no survival disparity by sex; female, OR=0.86 (95% CI 0.72-1.03, p=0.11)

Conclusion: Race/ethnicity, income, and access to chemotherapy and radiation therapy are associated with improved outcomes among patients with Burkitt Lymphoma. Conversely, the association between NHB and reduced survival can be explained by socioeconomic deprivation and lower access to treatment.

Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH